News on Gilead Sciences from BioPortfolio.com http://www.BioPortfolio.com Consolidated Gilead Sciences news from BioPortfolio.com Tue, 09 Feb 2010 23:26:20 GMT en Gilead Quad Pill Can Overtake Atripla, Milligan Says (Update1)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036695&HITNO=0&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036695&THISHREF=http://c.moreover.com/click/here.pl%3fz2536707453%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036695&HITNO=0&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036695&THISHREF=http://c.moreover.com/click/here.pl%3fz2536707453%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusinessWeek: Bay Biz Buzz: Google cuts phone termination feehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037673&HITNO=1&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037673&THISHREF=http://c.moreover.com/click/here.pl%3fz2537230810%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037673&HITNO=1&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037673&THISHREF=http://c.moreover.com/click/here.pl%3fz2537230810%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInside Bay Area: How one bull is playing Gileadhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032188&HITNO=2&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032188&THISHREF=http://c.moreover.com/click/here.pl%3fz2534541017%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032188&HITNO=2&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032188&THISHREF=http://c.moreover.com/click/here.pl%3fz2534541017%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comQuote.com Japan: UPDATE 1-Gilead sees big potential in new HIV pillhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037213&HITNO=3&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037213&THISHREF=http://c.moreover.com/click/here.pl%3fz2536965824%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037213&HITNO=3&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037213&THISHREF=http://c.moreover.com/click/here.pl%3fz2536965824%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSharenet: INTERVIEW-Gilead sees big potential in new HIV pillhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036976&HITNO=4&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036976&THISHREF=http://c.moreover.com/click/here.pl%3fz2536851540%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036976&HITNO=4&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036976&THISHREF=http://c.moreover.com/click/here.pl%3fz2536851540%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCNN Money: Short-Term Trader Is Cautiously Bullish on Gilead Sciences, Inchttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033145&HITNO=5&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033145&THISHREF=http://c.moreover.com/click/here.pl%3fz2535036812%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033145&HITNO=5&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033145&THISHREF=http://c.moreover.com/click/here.pl%3fz2535036812%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSchaeffers Research: Lightning Round: Nike, Visa, Gilead Sciences and More1http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036959&HITNO=6&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036959&THISHREF=http://c.moreover.com/click/here.pl%3fz2536843100%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036959&HITNO=6&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036959&THISHREF=http://c.moreover.com/click/here.pl%3fz2536843100%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCNBC: BRIEF-Gilead COO sees Atripla-size sales for new four-drug HIV pillhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036537&HITNO=7&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036537&THISHREF=http://c.moreover.com/click/here.pl%3fz2536649613%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036537&HITNO=7&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036537&THISHREF=http://c.moreover.com/click/here.pl%3fz2536649613%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInteractive Investor: India still not lucrative for innovator drugshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037961&HITNO=8&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037961&THISHREF=http://c.moreover.com/click/here.pl%3fz2537398536%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037961&HITNO=8&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037961&THISHREF=http://c.moreover.com/click/here.pl%3fz2537398536%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDNA India: A Look At How Different Sectors Will Behave In 2010 (PG, KO, WMT, GSK, GILD, AZN, EXC, D, DUK)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037569&HITNO=9&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037569&THISHREF=http://c.moreover.com/click/here.pl%3fz2537149623%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037569&HITNO=9&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037569&THISHREF=http://c.moreover.com/click/here.pl%3fz2537149623%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBenzinga.com: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=10&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=10&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHealthcare Sales & Marketing Network: Lightning Round: Nike, Visa, Gilead Sciences and Morehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034694&HITNO=11&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034694&THISHREF=http://c.moreover.com/click/here.pl%3fz2535927453%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034694&HITNO=11&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034694&THISHREF=http://c.moreover.com/click/here.pl%3fz2535927453%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCNBC: IPO Hopeful Anthera Gets SPA on Pivotal CV Outcomes Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032884&HITNO=12&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032884&THISHREF=http://c.moreover.com/click/here.pl%3fz2534847844%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032884&HITNO=12&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032884&THISHREF=http://c.moreover.com/click/here.pl%3fz2534847844%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: John T. Simmonshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034050&HITNO=13&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034050&THISHREF=http://c.moreover.com/click/here.pl%3fz2535582626%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034050&HITNO=13&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034050&THISHREF=http://c.moreover.com/click/here.pl%3fz2535582626%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMansfield News Journal: Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Programhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037712&HITNO=14&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037712&THISHREF=http://c.moreover.com/click/here.pl%3fz2537245827%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037712&HITNO=14&MSIZE=918&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Gilead%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037712&THISHREF=http://c.moreover.com/click/here.pl%3fz2537245827%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNational AIDS Treatment Advocacy Project: